On March 28, 2018, a Myeloma Crowd Round Table meeting was held in Baltimore, Maryland with a group of four regional myeloma experts, including:
Dr. Vesole: YouTube
Dr. Vesole speaks about the bone disease that affects 85% of multiple myeloma patients, and how bone hardening medicines may be the most important intervention in improving the life of myeloma patients.
Dr. Badros: YouTube
Dr. Badros believes the future of myeloma is to focus on high risk multiple myeloma patients. Better measures of disease progression, earlier therapy, improved imaging and new drugs and therapies will create a paradigm shift to improve patient outcomes.
Dr. Badros: YouTube pt. 2
Dr. Badros speaks about current exciting developments that are transforming the standard of care today in the treatment of multiple myeloma.
Dr. Borrello: YouTube
Dr. Borrello speaks about the integration of immunotherapy treatments into myeloma therapy. Immunotherapies have the potential to use the immune system to prevent disease progression and improve response to treatment with existing drugs. Checkpoint inhibitors, IMiDs, vaccines and CAR-T cells are revolutionizing the field of immunotherapy and present promising opportunities for the future.
Dr. Borrello: YouTube pt. 2
Dr. Borrello talks about the genetic evolution of myeloma, from a single plasma cell to multiple myeloma and plasma cell leukemia, as well as MRD negativity and transplant.
Morning Q&A: YouTube
Multiple Myeloma experts Ashraf Badros, MD, Ivan Borrello, MD and David Vesole, MD, PhD answer questions from the audience during the afternoon session of the Myeloma Crowd Round Table in Baltimore. Topics covered include:
Afternoon Q&A: YouTube
Multiple Myeloma experts Ashraf Badros, MD, Ivan Borrello, MD and David Vesole, MD, PhD answer questions from the audience during the afternoon session of the Myeloma Crowd Round Table in Baltimore. Topics covered include:
Thanks to our Sponsors
On March 28, 2018, a Myeloma Crowd Round Table meeting was held in Baltimore, Maryland with a group of four regional myeloma experts, including:
Dr. Vesole: YouTube
Dr. Vesole speaks about the bone disease that affects 85% of multiple myeloma patients, and how bone hardening medicines may be the most important intervention in improving the life of myeloma patients.
Dr. Badros: YouTube
Dr. Badros believes the future of myeloma is to focus on high risk multiple myeloma patients. Better measures of disease progression, earlier therapy, improved imaging and new drugs and therapies will create a paradigm shift to improve patient outcomes.
Dr. Badros: YouTube pt. 2
Dr. Badros speaks about current exciting developments that are transforming the standard of care today in the treatment of multiple myeloma.
Dr. Borrello: YouTube
Dr. Borrello speaks about the integration of immunotherapy treatments into myeloma therapy. Immunotherapies have the potential to use the immune system to prevent disease progression and improve response to treatment with existing drugs. Checkpoint inhibitors, IMiDs, vaccines and CAR-T cells are revolutionizing the field of immunotherapy and present promising opportunities for the future.
Dr. Borrello: YouTube pt. 2
Dr. Borrello talks about the genetic evolution of myeloma, from a single plasma cell to multiple myeloma and plasma cell leukemia, as well as MRD negativity and transplant.
Morning Q&A: YouTube
Multiple Myeloma experts Ashraf Badros, MD, Ivan Borrello, MD and David Vesole, MD, PhD answer questions from the audience during the afternoon session of the Myeloma Crowd Round Table in Baltimore. Topics covered include:
Afternoon Q&A: YouTube
Multiple Myeloma experts Ashraf Badros, MD, Ivan Borrello, MD and David Vesole, MD, PhD answer questions from the audience during the afternoon session of the Myeloma Crowd Round Table in Baltimore. Topics covered include:
Thanks to our Sponsors
about the author
Erika Johnson
Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.